Guardant Health (NASDAQ: GH) reported Q4 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $62.9 million versus the consensus estimate of $54.83 million.

GUIDANCE:

Guardant Health sees FY2020 revenue of $275-285 million, versus the consensus of $273.1 million.

• Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020.

For earnings history and earnings-related data on Guardant Health (GH) click here.